CorMedix (NASDAQ:CRMD) executives used a presentation at the Citizens Life Sciences Conference to outline the company’s focus on expanding its pipeline while integrating the recently acquired Melinta Therapeutics assets and navigating evolving reimbursement dynamics for its catheter lock solution DefenCath.
Company overview and pipeline priorities
Chief Executive Officer Joe Todisco described CorMedix as a specialty pharmaceutical company with a broad portfolio of mostly injectable drugs used in institutional settings, with many of its marketed products in anti-infective categories. He said the company is “focusing heavily” on development-stage opportunities, highlighting two main programs:
- REZZAYO in a phase III trial evaluating prophylaxis of fungal infections in immunocompromised patients.
- DefenCath in phase III studies for prevention of catheter-related bloodstream infections (CLABSI) in patients receiving IV nutrition therapy (total parenteral nutrition, or TPN).
REZZAYO prophylaxis study: timing, endpoints, and differentiation
REZZAYO is currently approved for treatment of Candida infections, and CorMedix is studying it as a prophylactic therapy in allogeneic bone marrow transplant patients. Todisco said the phase III readout is expected in the second quarter, with current expectations “probably” later in the quarter.
He explained that the study is a head-to-head trial against standard prophylaxis regimens, which typically involve an azole (posaconazole or fluconazole) combined with Bactrim. The primary endpoint is fungal-free survival at day 90 and is structured as a non-inferiority endpoint versus standard of care. The company is also focused on discontinuation rates as a key secondary endpoint.
Todisco pointed to what he described as shortcomings of current standard prophylaxis options, including hepatotoxicity and drug-drug interactions, suggesting REZZAYO could differentiate on tolerability and discontinuation. He said CorMedix has a “high degree of confidence” in REZZAYO’s activity against multiple pathogens—Candida, Aspergillus, and Pneumocystis—citing preclinical work, treatment data in Candida, and ongoing phase II treatment studies in Aspergillus and Pneumocystis. However, he noted that pathogen representation in the phase III trial remains blinded to the company.
Commercial execution and market size for REZZAYO
On REZZAYO’s current on-label commercial experience, Todisco said it remains early and is constrained by a smaller total addressable market (TAM) tied to the current treatment label. CorMedix acquired Melinta less than six months ago, and Todisco said the company has been evaluating what it can do differently to improve “pull through” and better support the patient journey, including transitions from inpatient hospital care to outpatient infusion clinics.
In prophylaxis, Todisco framed the opportunity as substantially larger and discussed how CorMedix sizes the market. He said prophylaxis associated with bone marrow transplant represents about $500 million, while the total number of patients receiving prophylaxis for various pathogens represents more than $2 billion. He broke that larger figure into approximately $1.4 billion for patients receiving multi-pathogen prophylaxis (Candida, Aspergillus, Pneumocystis) and about $800 million for patients continuing on Pneumocystis-only prophylaxis.
He also identified solid organ transplant patients as another significant prophylaxis population, noting that duration of antifungal therapy can vary by transplanted organ. Todisco said CorMedix has received requests for investigator-initiated trials (IITs) in areas such as organ transplant, and he expects use could “organically” expand beyond the company’s initial promotional focus.
On payer access, Todisco acknowledged REZZAYO could be more expensive than generic azoles but argued the cost of prophylaxis is small relative to the overall cost of care for these patients. He said discussions with payers will still be needed and suggested safety and discontinuation could be meaningful elements of the value proposition.
Regarding commercial infrastructure, he said CorMedix has a field organization largely stemming from legacy Melinta, with market access and key account management combining CorMedix and Melinta personnel. He reiterated previously guided cash operating expense of $145 million to $160 million and said the higher end reflects the potential addition of about 15 to 20 incremental hires later in the year, contingent on REZZAYO prophylaxis data, including commercial contracting experience in hematology/oncology clinics and additional medical science liaisons with hematology backgrounds.
Melinta integration and DefenCath reimbursement dynamics
Todisco characterized the Melinta transaction as part of a strategy to diversify CorMedix beyond DefenCath, which he described as having “atypical reimbursement” under TDAPA. He said DefenCath experiences a bolus of revenue in the first 24 months and then faces price erosion, creating a need to grow volume over time. He said CorMedix sought a synergistic, stable base of revenue with growth potential and identified Melinta as the top target in late 2024.
He highlighted products including Vabomere and Minocin as established anti-infectives that do not require large SG&A to maintain sales, and described Rocephin as a “big growth opportunity.” He said the company has about 35 key account managers, roughly 12 market access personnel, plus communications and analytics resources, totaling around 80 heads across the commercial organization.
Discussing profitability and cash flow, Todisco said the Melinta assets contribute stable cash flow and help the company manage an anticipated reimbursement transition for DefenCath. He said CMS is transitioning DefenCath to bundled reimbursement starting in July, creating a two-quarter period where reimbursement will be lower in the third and fourth quarters, with reimbursement expected to increase in 2027. He said the company added “$150 million” of stable base revenue to help “weather that cycle.”
On DefenCath growth, Todisco said more than 95% of CorMedix’s DefenCath business currently comes from Medicare fee-for-service patients. He identified Medicare Advantage as the “largest untapped market opportunity,” noting Medicare Advantage patients represent about half of end-stage renal disease (ESRD) patients and could rise materially over time. CorMedix is using real-world evidence data from U.S. Renal Care to make the case for separate reimbursement by Medicare Advantage plans, emphasizing an interim analysis that showed a 70% reduction in hospitalizations. He said the effort began in January and remains early, but feedback has been positive that the approach “makes medical sense.”
Todisco also said CorMedix is actively supplying Fresenius as a large dialysis organization customer but did not provide patient counts, citing confidentiality.
In TPN, Todisco said CorMedix has adjusted expectations and now anticipates potential study completion in early 2027, rather than late 2026. Enrollment is just under 30%. The adaptive study design has a minimum of 90 patients and maximum of 200, with an interim look after 15 cumulative infections to determine whether the trial could finish at 90 patients or continue toward 200. He said the company believes DefenCath’s efficacy should translate to TPN based on prior results in the LOCK-IT study and real-world experience, while noting TPN reimbursement is expected to differ from dialysis because it is generally under Medicare Part B rather than a bundled payment system. He also noted plans to seek a separate J-code and differentiate pricing by therapeutic setting.
Looking ahead, Todisco said CorMedix’s appetite for additional transactions has shifted from “transformational” to more “tuck-in” opportunities that fit existing or future commercial call points, generally funded through cash on hand and potentially debt rather than equity.
About CorMedix (NASDAQ:CRMD)
CorMedix Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to reduce inflammation and prevent infection in critically and chronically ill patient populations. The company’s lead product candidate, Neutrolin, is a catheter lock solution that combines taurolidine, heparin and citrate to prevent catheter-related bloodstream infections (CRBSIs) in patients undergoing hemodialysis. Neutrolin has received market authorization in the European Union under the CE Mark and is positioned to address a significant unmet medical need for infection prevention in dialysis centers.
In addition to its lead asset, CorMedix is advancing a biochemical portfolio aimed at mitigating complications associated with peritoneal dialysis and other high-risk procedures.
